Radiopharmaceticals and supples
Ended Awarded Last action
- Contract number
- W81K0024F0143
- Awardee
-
Lantheus Medical Imaging, Inc. UEI ZBTPKVDXCKJ7 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $99,986
Award facts
- Contract value 100% obligated
- $99,986.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Bliss, TX 79918, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$10 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $99,996 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a $99,986.35 firm fixed-price blanket purchase agreement call to Lantheus Medical Imaging, Inc. for the supply of Xenon-133 gas radiopharmaceuticals. The contract, which became effective October 1, 2024, with completion targeted for September 30, 2025, represents a delivery order against Lantheus Medical Imaging's existing $6.5 million blanket purchase agreement established in July 2023 under the General Services Administration Pharmaceuticals and Drugs Federal Supply Schedule. No small business set-aside designation was applied to this award. The performance location is Fort Bliss, Texas, where the radiopharmaceutical supplies will support medical imaging and diagnostic capabilities at military treatment facilities.
Lantheus Medical Imaging, Inc., a Massachusetts-based subsidiary of Lantheus Holdings, Inc., is a leading federal supplier of nuclear medicine diagnostic imaging agents and radiopharmaceutical products. The company has established an extensive contracting relationship with the Defense Health Agency and serves as a critical provider to military medical centers and Veterans Affairs facilities nationwide. Xenon-133 is a diagnostic radiopharmaceutical used in nuclear medicine imaging procedures, and this contract ensures the continued availability of this essential imaging agent to support the Defense Health Agency's medical diagnostic operations across its healthcare network.
Quick answers
Who was awarded contract W81K0024F0143?
W81K0024F0143 was awarded to Lantheus Medical Imaging, Inc. by Medical Command (Department of the Army) on October 1, 2024.
How much is contract W81K0024F0143 worth?
The government has obligated $99,986 on W81K0024F0143.
Which agency awarded contract W81K0024F0143?
Medical Command (Department of the Army) awarded W81K0024F0143, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0024F0143 an order under another contract?
Yes. W81K0024F0143 is a BPA call under W81K0020A0013, a blanket purchase agreement.
Was contract W81K0024F0143 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award